Cargando…

COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19

The COVID-19 pandemic poses a huge problem of public health that requires the implementation of all available means to contrast it, and drugs are one of them. In this context, we observed an unmet need of depicting the continuously evolving scenario of the ongoing drug clinical trials through an eas...

Descripción completa

Detalles Bibliográficos
Autores principales: Menestrina, Luca, Cabrelle, Chiara, Recanatini, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484553/
https://www.ncbi.nlm.nih.gov/pubmed/34593915
http://dx.doi.org/10.1038/s41598-021-98812-0
_version_ 1784577342573641728
author Menestrina, Luca
Cabrelle, Chiara
Recanatini, Maurizio
author_facet Menestrina, Luca
Cabrelle, Chiara
Recanatini, Maurizio
author_sort Menestrina, Luca
collection PubMed
description The COVID-19 pandemic poses a huge problem of public health that requires the implementation of all available means to contrast it, and drugs are one of them. In this context, we observed an unmet need of depicting the continuously evolving scenario of the ongoing drug clinical trials through an easy-to-use, freely accessible online tool. Starting from this consideration, we developed COVIDrugNet (http://compmedchem.unibo.it/covidrugnet), a web application that allows users to capture a holistic view and keep up to date on how the clinical drug research is responding to the SARS-CoV-2 infection. Here, we describe the web app and show through some examples how one can explore the whole landscape of medicines in clinical trial for the treatment of COVID-19 and try to probe the consistency of the current approaches with the available biological and pharmacological evidence. We conclude that careful analyses of the COVID-19 drug-target system based on COVIDrugNet can help to understand the biological implications of the proposed drug options, and eventually improve the search for more effective therapies.
format Online
Article
Text
id pubmed-8484553
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84845532021-10-04 COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19 Menestrina, Luca Cabrelle, Chiara Recanatini, Maurizio Sci Rep Article The COVID-19 pandemic poses a huge problem of public health that requires the implementation of all available means to contrast it, and drugs are one of them. In this context, we observed an unmet need of depicting the continuously evolving scenario of the ongoing drug clinical trials through an easy-to-use, freely accessible online tool. Starting from this consideration, we developed COVIDrugNet (http://compmedchem.unibo.it/covidrugnet), a web application that allows users to capture a holistic view and keep up to date on how the clinical drug research is responding to the SARS-CoV-2 infection. Here, we describe the web app and show through some examples how one can explore the whole landscape of medicines in clinical trial for the treatment of COVID-19 and try to probe the consistency of the current approaches with the available biological and pharmacological evidence. We conclude that careful analyses of the COVID-19 drug-target system based on COVIDrugNet can help to understand the biological implications of the proposed drug options, and eventually improve the search for more effective therapies. Nature Publishing Group UK 2021-09-30 /pmc/articles/PMC8484553/ /pubmed/34593915 http://dx.doi.org/10.1038/s41598-021-98812-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Menestrina, Luca
Cabrelle, Chiara
Recanatini, Maurizio
COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
title COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
title_full COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
title_fullStr COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
title_full_unstemmed COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
title_short COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
title_sort covidrugnet: a network-based web tool to investigate the drugs currently in clinical trial to contrast covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484553/
https://www.ncbi.nlm.nih.gov/pubmed/34593915
http://dx.doi.org/10.1038/s41598-021-98812-0
work_keys_str_mv AT menestrinaluca covidrugnetanetworkbasedwebtooltoinvestigatethedrugscurrentlyinclinicaltrialtocontrastcovid19
AT cabrellechiara covidrugnetanetworkbasedwebtooltoinvestigatethedrugscurrentlyinclinicaltrialtocontrastcovid19
AT recanatinimaurizio covidrugnetanetworkbasedwebtooltoinvestigatethedrugscurrentlyinclinicaltrialtocontrastcovid19